β2-Chimaerin, a GTPase-Activating Protein for Rac1, Is a Novel Regulator of Hepatic Insulin Signaling and Glucose Metabolism
Molecules · 2024
DOI: 10.3390/molecules29225301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Cristian Andrés Carmona-Carmona und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biomedicina y Genética Molecular (IBGM), CSIC-UVA, 47003 Valladolid, Spain. Hauptthemen laut MEDLINE: Insulin, rac1 GTP-Binding Protein, Liver, Signal Transduction. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Junta de Castilla y León, Castilla-León Autonomous Government (Consejería de Sanidad), Programa Estrategico IBGM, Escalera de Excelencia.
Abstract (Originalsprache)
Glucose homeostasis is a complex process regulated by multiple organs and hormones, with insulin playing a central role. Recent evidence underscores the role of small GTP-binding proteins, particularly Rac1, in regulating insulin secretion and glucose uptake. However, the role of Rac1-regulatory proteins in these processes remains largely unexplored. In this study, we investigated the role of β2-chimaerin, a Rac1-specific GTPase-activating protein (GAP), in glucose homeostasis using whole-body β2-chimaerin knockout mice. Our data revealed that β2-chimaerin deficiency results in improved glucose tolerance and enhanced insulin sensitivity in mice. These metabolic effects were associated with increased insulin-induced AKT phosphorylation in the liver and activation of downstream pathways that regulate gluconeogenesis and glycogen synthesis. We show that insulin activates Rac1 in the liver. However, β2-chimaerin deletion did not significantly alter Rac1 activation in this organ, suggesting that β2-chimaerin regulates insulin signaling via a Rac1-independent mechanism. These findings expand our understanding of Rac1 regulation in glucose metabolism, and identify β2-chimaerin as a novel modulator of hepatic insulin signaling, with potential implications for the development of insulin resistance and diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Biomedicina y Genética Molecular (IBGM), CSIC-UVA, 47003 Valladolid, Spain.
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain.
ORCID-Profile: Cristian Andrés Carmona-Carmona, Eladio A Velasco-Sampedro, Irene Cózar-Castellano, Germán Perdomo, María J Caloca
Förderung
- Junta de Castilla y León
- Castilla-León Autonomous Government (Consejería de Sanidad)
- Programa Estrategico IBGM, Escalera de Excelencia
- Consejería de Educación, Junta de Castilla y León (Spain)
Zitieren
APA
Carmona-Carmona, C. A., Zini, P., Velasco-Sampedro, E. A., Cózar-Castellano, I., Perdomo, G., & Caloca, M. J. (2024). β2-Chimaerin, a GTPase-Activating Protein for Rac1, Is a Novel Regulator of Hepatic Insulin Signaling and Glucose Metabolism. Molecules. https://doi.org/10.3390/molecules29225301
Vancouver
Carmona-Carmona CA, Zini P, Velasco-Sampedro EA, Cózar-Castellano I, Perdomo G, Caloca MJ. β2-Chimaerin, a GTPase-Activating Protein for Rac1, Is a Novel Regulator of Hepatic Insulin Signaling and Glucose Metabolism. Molecules. 2024. doi:10.3390/molecules29225301
BibTeX
@article{CarmonaCarmona2024,
author = {Carmona-Carmona, Cristian Andrés and Zini, Pablo and Velasco-Sampedro, Eladio A and Cózar-Castellano, Irene and Perdomo, Germán and Caloca, María J},
title = {β2-Chimaerin, a GTPase-Activating Protein for Rac1, Is a Novel Regulator of Hepatic Insulin Signaling and Glucose Metabolism},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29225301}
}
EUVIMED